Physician profile
Christine E Dahlin
NPI 1922293786
$1,045.83
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $718 · 2020: $328.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $568.52 | 2019-2020 | |
| Radius Health, INC. | $92.74 | 2019-2020 | |
| Eisai INC. | $55.70 | 2019 | |
| Lilly USA, LLC | $54.81 | 2019-2020 | |
| Vertiflex, INC. | $47.06 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $39.89 | 2019-2020 | |
| Ibsa Pharma INC. | $30.54 | 2019-2020 | |
| Glaxosmithkline, LLC. | $23.98 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.76 | 2019 | |
| Novartis Pharmaceuticals Corporation | $20.65 | 2019 | |
| Merck Sharp & Dohme LLC | $19.99 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $19.19 | 2019 | |
| Novo Nordisk INC | $17.73 | 2020 | |
| Boston Scientific Corporation | $15.94 | 2019 | |
| Bausch Health US, LLC | $15.33 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Dahlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.